Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDInnate Pharma S.A. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Innate Pharma S.A. Earnings Date And Information
Innate Pharma S.A. last posted its earnings results on Tuesday, November 17th, 2020. The company reported $-0.13099 earnings per share for the quarter, topping analysts' consensus estimates of $-0.33601 by $0.20502. The company had revenue of 12.35 M for the quarter and had revenue of 51.90 M for the year. Innate Pharma S.A. has generated $0 earnings per share over the last year ($-0.0941 diluted earnings per share) and currently has a price-to-earnings ratio of -4.46. Innate Pharma S.A. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Innate Pharma S.A. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/12/2024 | Q2 2024 | N/A | -$0.31 | N/A | $10.30 M | $12.35 M |
| 12/29/2023 | Q4 2023 | N/A | -$0.12 | N/A | N/A | $21.44 M |
| 06/29/2023 | Q2 2023 | N/A | $0.02 | N/A | N/A | $35.34 M |
| 12/30/2022 | Q4 2022 | N/A | -$0.80 | N/A | N/A | $8.31 M |
| 06/29/2022 | Q2 2022 | N/A | $0.08 | N/A | N/A | $41.27 M |
| 12/30/2021 | Q4 2021 | N/A | -$0.37 | N/A | N/A | $2.79 M |
| 06/29/2021 | Q2 2021 | N/A | -$0.30 | N/A | N/A | $9.32 M |
| 12/30/2020 | Q4 2020 | N/A | -$0.68 | N/A | N/A | $26.99 M |
| 06/29/2020 | Q2 2020 | N/A | -$0.13 | N/A | N/A | $36.75 M |
| 12/30/2019 | Q4 2019 | N/A | -$0.52 | N/A | N/A | $17.39 M |
| 06/29/2019 | Q2 2019 | N/A | $0.21 | N/A | N/A | $51.59 M |
| 12/30/2018 | Q4 2018 | N/A | $0.30 | N/A | N/A | $70.96 M |
| 06/29/2018 | Q2 2018 | N/A | -$0.26 | N/A | N/A | $23.00 M |
| 12/30/2017 | Q4 2017 | N/A | -$0.46 | N/A | N/A | $22.76 M |
| 06/29/2017 | Q2 2017 | N/A | -$0.44 | N/A | N/A | $21.27 M |
| 12/30/2016 | Q4 2016 | N/A | $0.28 | N/A | N/A | $45.04 M |
| 06/29/2016 | Q2 2016 | N/A | -$0.06 | N/A | N/A | $20.69 M |
| 12/30/2015 | Q4 2015 | N/A | $0.02 | N/A | N/A | $20.50 M |
| 06/29/2015 | Q2 2015 | N/A | -$0.15 | N/A | N/A | $4.64 M |
| 12/30/2014 | Q4 2014 | N/A | -$0.20 | N/A | N/A | $3.49 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Innate Pharma S.A. Earnings: FAQ's
Innate Pharma S.A. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based offlast year's report dates.
In the previous quarter, Innate Pharma S.A. (:IPHA) reported $-0.13099 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.33601 by $0.20502.
The conference call for Innate Pharma S.A.'s latest earnings report can be listened to online.
The conference call transcript for Innate Pharma S.A.'s latest earnings report can be read online.
Innate Pharma S.A. (:IPHA) has a recorded annual revenue of $51.90 M.
Innate Pharma S.A. (:IPHA) has a recorded net income of $-7,570,000.Innate Pharma S.A. has generated $-0.0941 earnings per share over the last four quarters.
Innate Pharma S.A. (:IPHA) has a price-to-earnings ratio of -4.46 and price/earnings-to-growth ratio is 0.01.